-
Asymptotically perfect seeded graph matching without edge correlation (and applications to inference)
Authors:
Tong Qi,
Vera Andersson,
Peter Viechnicki,
Vince Lyzinski
Abstract:
We present the OmniMatch algorithm for seeded multiple graph matching. In the setting of $d$-dimensional Random Dot Product Graphs (RDPG), we prove that under mild assumptions, OmniMatch with $s$ seeds asymptotically and efficiently perfectly aligns $O(s^α)$ unseeded vertices -- for $α<2\wedge d/4$ -- across multiple networks even in the presence of no edge correlation. We demonstrate the effectiv…
▽ More
We present the OmniMatch algorithm for seeded multiple graph matching. In the setting of $d$-dimensional Random Dot Product Graphs (RDPG), we prove that under mild assumptions, OmniMatch with $s$ seeds asymptotically and efficiently perfectly aligns $O(s^α)$ unseeded vertices -- for $α<2\wedge d/4$ -- across multiple networks even in the presence of no edge correlation. We demonstrate the effectiveness of our algorithm across numerous simulations and in the context of shuffled graph hypothesis testing. In the shuffled testing setting, testing power is lost due to the misalignment/shuffling of vertices across graphs, and we demonstrate the capacity of OmniMatch to correct for misaligned vertices prior to testing and hence recover the lost testing power. We further demonstrate the algorithm on a pair of data examples from connectomics and machine translation.
△ Less
Submitted 2 July, 2025; v1 submitted 3 June, 2025;
originally announced June 2025.
-
Detection of Model-based Planted Pseudo-cliques in Random Dot Product Graphs by the Adjacency Spectral Embedding and the Graph Encoder Embedding
Authors:
Tong Qi,
Vince Lyzinski
Abstract:
In this paper, we explore the capability of both the Adjacency Spectral Embedding (ASE) and the Graph Encoder Embedding (GEE) for capturing an embedded pseudo-clique structure in the random dot product graph setting. In both theory and experiments, we demonstrate that this pairing of model and methods can yield worse results than the best existing spectral clique detection methods, demonstrating a…
▽ More
In this paper, we explore the capability of both the Adjacency Spectral Embedding (ASE) and the Graph Encoder Embedding (GEE) for capturing an embedded pseudo-clique structure in the random dot product graph setting. In both theory and experiments, we demonstrate that this pairing of model and methods can yield worse results than the best existing spectral clique detection methods, demonstrating at once the methods' potential inability to capture even modestly sized pseudo-cliques and the methods' robustness to the model contamination giving rise to the pseudo-clique structure. To further enrich our analysis, we also consider the Variational Graph Auto-Encoder (VGAE) model in our simulation and real data experiments.
△ Less
Submitted 18 December, 2023;
originally announced December 2023.
-
A Flexible Approach for Predictive Biomarker Discovery
Authors:
Philippe Boileau,
Nina Ting Qi,
Mark J. van der Laan,
Sandrine Dudoit,
Ning Leng
Abstract:
An endeavor central to precision medicine is predictive biomarker discovery; they define patient subpopulations which stand to benefit most, or least, from a given treatment. The identification of these biomarkers is often the byproduct of the related but fundamentally different task of treatment rule estimation. Using treatment rule estimation methods to identify predictive biomarkers in clinical…
▽ More
An endeavor central to precision medicine is predictive biomarker discovery; they define patient subpopulations which stand to benefit most, or least, from a given treatment. The identification of these biomarkers is often the byproduct of the related but fundamentally different task of treatment rule estimation. Using treatment rule estimation methods to identify predictive biomarkers in clinical trials where the number of covariates exceeds the number of participants often results in high false discovery rates. The higher than expected number of false positives translates to wasted resources when conducting follow-up experiments for drug target identification and diagnostic assay development. Patient outcomes are in turn negatively affected. We propose a variable importance parameter for directly assessing the importance of potentially predictive biomarkers, and develop a flexible nonparametric inference procedure for this estimand. We prove that our estimator is double-robust and asymptotically linear under loose conditions on the data-generating process, permitting valid inference about the importance metric. The statistical guarantees of the method are verified in a thorough simulation study representative of randomized control trials with moderate and high-dimensional covariate vectors. Our procedure is then used to discover predictive biomarkers from among the tumor gene expression data of metastatic renal cell carcinoma patients enrolled in recently completed clinical trials. We find that our approach more readily discerns predictive from non-predictive biomarkers than procedures whose primary purpose is treatment rule estimation. An open-source software implementation of the methodology, the uniCATE R package, is briefly introduced.
△ Less
Submitted 1 June, 2022; v1 submitted 2 May, 2022;
originally announced May 2022.
-
The Future will be Different than Today: Model Evaluation Considerations when Developing Translational Clinical Biomarker
Authors:
Yichen Lu,
Jane Fridlyand,
Tiffany Tang,
Ting Qi,
Noah Simon,
Ning Leng
Abstract:
Finding translational biomarkers stands center stage of the future of personalized medicine in healthcare. We observed notable challenges in identifying robust biomarkers as some with great performance in one scenario often fail to perform well in new trials (e.g. different population, indications). With rapid development in the clinical trial world (e.g. assay, disease definition), new trials ver…
▽ More
Finding translational biomarkers stands center stage of the future of personalized medicine in healthcare. We observed notable challenges in identifying robust biomarkers as some with great performance in one scenario often fail to perform well in new trials (e.g. different population, indications). With rapid development in the clinical trial world (e.g. assay, disease definition), new trials very likely differ from legacy ones in many perspectives and in development of biomarkers this heterogeneity should be considered. In response, we recommend considering building in the heterogeneity when evaluating biomarkers. In this paper, we present one evaluation strategy by using leave-one-study-out (LOSO) in place of conventional cross-validation (cv) methods to account for the potential heterogeneity across trials used for building and testing the biomarkers. To demonstrate the performance of K-fold vs LOSO cv in estimating the effect size of biomarkers, we leveraged data from clinical trials and simulation studies. In our assessment, LOSO cv provided a more objective estimate of the future performance. This conclusion remained true across different evaluation metrics and different statistical methods.
△ Less
Submitted 13 July, 2021;
originally announced July 2021.
